Therapeutic Drug Monitoring of Anxiolytics in Children
Overview
- Phase
- Phase 4
- Intervention
- Midazolam/diazepam/propofol
- Conditions
- Anxiolytics
- Sponsor
- Wei Zhao
- Enrollment
- 500
- Locations
- 1
- Primary Endpoint
- Plasma drug concentration
- Last Updated
- 6 years ago
Overview
Brief Summary
In this study, the therapeutic drug monitoring of anxiolytics is carried out among children to obtain the drug concentration, clinical efficacy and safety data of children patients in different gender and age groups. Then the investigators analyze the relationship between blood drug concentration and efficacy and safety, and provide recommendations for the treatment window of anxiolytics in Chinese children.
Investigators
Wei Zhao
Professor; Head of department of clinical pharmacy and pharmacology
Shandong University
Eligibility Criteria
Inclusion Criteria
- •Anxiolytics was used for therapeutic purposes;
- •Age:≤18 years;
- •Patients with therapeutic concentration monitoring of anxiolytics.
Exclusion Criteria
- •Patients without therapeutic concentration monitoring of anxiolytics;
- •The blood concentrations of the patient was not approved by the quality control center
- •Use foods or products that inhibit or induce CYP 3A activity.
Arms & Interventions
Anxiolytics
Pediatric patients treated with sedation using anxiolytics
Intervention: Midazolam/diazepam/propofol
Outcomes
Primary Outcomes
Plasma drug concentration
Time Frame: Through study completion, an average of 14 days
To detect the plasma concentrations of teicoplanin at therapeutic drug monitoring (TDM).